The past is the future: Innovative designs in acute stroke therapy trials

Stroke

Volumn 36, Issue 6, 2005, Pages 1341-1347

  Krams, Michael ^a   Lees, Kennedy R ^b   Berry, Donald A ^c,d  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b WESTERN INFIRMARY   (United Kingdom)

^c M D Anderson ^*  (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Models, theoretical; Neuroprotection

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT;

ACUTE DISEASE; BAYES THEOREM; CEREBROVASCULAR DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; DOSE RESPONSE; FIBRINOLYTIC THERAPY; HUMAN; MODEL; NEUROPROTECTION; PRIORITY JOURNAL; REVIEW; STROKE;

BAYES THEOREM; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; HUMANS; MODELS, STATISTICAL; MODELS, THEORETICAL; NEUROPROTECTIVE AGENTS; RESEARCH DESIGN; SAMPLE SIZE;

EID: 20444393946     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000165931.77045.ee     Document Type: Review

References (19)

1. th century. Stroke. 2001;32:1349-1359.
2. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
3. Grotta J. Neuroprotection is unlikely to be effective in humans using current trial designs. Stroke. 2002;33:306-307.
4. Lees KR. Neuroprotection is unlikely to be effective in humans using current trial designs: an opposing view. Stroke. 2002;33:308-309.
5. Berry DA. Clinical trials: is the Bayesian approach ready for primetime? Yes! Stroke. 2005; In press.
6. th ed. London: BC Decker; 2003:465-478.
7. Berry DA. Bayesian statistics and the efficiency and ethics of clinical trials. Stat Sci. 2004;19:175-187.
8. Giles FJ, Kantarjian HM, Cortes JE, Garcia-Manero G, Verstovsek S, Faderl S, Thomas DA, Ferrajoli A, O'Brien S, Wathen JK, Xiao L-C, Berry DA, Estey EH. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol 2003;21:1722-1727.
9. Berry DA. Statistics: a Bayesian perspective. Belmont, CA: Duxbury Press; 1996.
10. Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo JM, Ford GA; for the ASTIN Study Investigators. ASTIN: an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke, 2003;34:2543-2548.
11. Jorgensen HS, Nakayama H, Raaschou HO, Vive-Larsen J, Stoier M, Olsen TS. Outcome and time course of recovery in stroke, the Copenhagen Stroke Study. Arch Phys Med Rehabil. 1995;76:399-412.
12. Berry DA, Mueller P, Grieve AP, Smith MK, Parke T, Krams M. Bayesian Designs for dose-ranging drug trials. In: Gatsonis C, Kass RE. Carlin B, Carriquiry A, Gelman A, Verdinelli I, West M, eds. Case Studies in Bayesian Statistics, vol 5. New York: Springer-Verlag; 2002:99-181.
13. Diener HC, Cortens M, Ford G, Grotta J, Hacke W, Kaste M, Koudstaal PJ, Wessel T. Lubeluzole in acute ischemic stroke treatment: A double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. Stroke. 2000;31:2543-2551.
14. Berry DA. Decision analysis and Bayesian methods in clinical trials. In: Thaii PF, ed. Recent Advances In Clinical Trial Design and Analysis. New York: Kluwer Press: 1995:125-154.
15. Lewis RJ, Berry DA. Decision theory. In: Armitage P, Colton T, eds. Encyclopedia of Biostatistics, vol 2. New York: John Wiley & Sons; 1998:1109-1118.
16. Cheng Y, Su F, Berry DA. Choosing sample size for a clinical trial using decision analysis. Biometrika. 2003;90:923-936.
17. Inoue LYT, Thall P, Berry DA, Seamlessly expanding a randomized phase II trial to phase III. Biometrics. 2002:58:264-272.
18. Adams HP, Leclerc JR, Bluhmki E, Clarke W, Hansen MD, Hacke W. Measuring outcomes as a function of baseline severity of ischemic stroke. Cerebrovasc Dis. 2004;18:124-129.
19. Stroke Therapy Academic Industry Roundtable 4. Recommendations for advancing development of acute stroke therapies. Stroke. 2005; In press.